Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Capecitabine and Radiotherapy in Resistant Breast Cancer
NCT03958721Phase 1Completed
- Start
- Jul 2019
- Primary completion
- Oct 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capecitabine in breast cancer. Primary endpoint: Percentage of patients who complete concurrent capecitabine-radiotherapy up to 6 months. Started Jul 2019; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03958721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958721.